Premium
New River Pharmaceuticals (MM) (NRPH)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
NEW YORK, April 18 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the...
RADFORD, Va., April 3 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that, in connection with its previously disclosed pending acquisition by Shire plc...
RADFORD, Va., March 19 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that the waiting period under the Hart- Scott-Rodino Antitrust Improvements Act of...
RADFORD, Va., March 13 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced its financial results for the year ended December 31, 2006. New River recognized a...
BASINGSTOKE, England, PHILADELPHIA, Pennsylvania and Radford, VIRGINIA, February 23 /PRNewswire-FirstCall/ -- Shire plc (LSE:SHPLSE:NASDAQ:LSE:SHPGYLSE: TSX:LSE:SHQ) and its collaborative...
RADFORD, Va., Feb. 20 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it has signed a definitive agreement with Shire plc...
RADFORD, Va., Feb. 5 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it plans to present at the 2007 Merrill Lynch Global Pharmaceutical...
RADFORD, Va., Jan. 25 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that James P. Shaffer has been appointed the company's Vice President, Sales and...
Launch Expected Q2 2007 BASINGSTOKE, U.K., PHILADELPHIA and RADFORD, Va., Dec. 21 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) and its collaborative partner Shire plc...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
